# NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

Product · id `cardio:fdaprod-nda214313` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [openFDA record NDA214313](<https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214313>), retrieved 18 November 2026. No person wrote or checked this page.

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Acute care and long-term living  

## In plain language

A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand names.

## Technical summary

Drugs@FDA application NDA214313. Original approval 2021-01-15. No efficacy supplement approvals are on record. 6 products listed.

## The registry's words

- Application: NDA214313
- Brand name: NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
- Brand name: NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
- Applicant: BAXTER HLTHCARE CORP
- Active ingredient: NOREPINEPHRINE BITARTRATE
- Dosage form: SOLUTION
- Route: INTRAVENOUS

## Claims, with the population each applies to

## Context: FDA record read by the openFDA feed

Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)

### FDA records an approval of NDA214313 on 2021-01-15.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application NDA214313 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214313>
     Locator: submissions\[0\].submission\_status\_date. Retrieved 2026-11-18T16:02:17Z. Source state: Current. Version fingerprint: c76f89a5c1df6cbcc970b30d573e65db201c922e39333b69ccadd1806887667a.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application NDA214313 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214313>
     Locator: application\_number. Retrieved 2026-11-18T16:02:17Z. Source state: Current. Version fingerprint: c76f89a5c1df6cbcc970b30d573e65db201c922e39333b69ccadd1806887667a.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application NDA214313 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214313>
     Locator: submissions\[0\].submission\_status. Retrieved 2026-11-18T16:02:17Z. Source state: Current. Version fingerprint: c76f89a5c1df6cbcc970b30d573e65db201c922e39333b69ccadd1806887667a.
     How it applies: The decision status as the record writes it.

## Guidance, authorization and access

### Regulatory decision `cardio:fdadec-nda214313-approval`

- Product: NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE (`cardio:fdaprod-nda214313`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Approval, 2021-01-15
- Product version: Original application
- Pathway: NDA
- Submission: NDA214313
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-nda214313-approval`

## Connected pages

- Registry active ingredient is this drug: Norepinephrine (`cardio:norepinephrine`)

## Provenance

Content hash: 17c9fdbe206565caa8078525a6c9da03f12efc642a975fba92726a65d6aa8f0e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
